Dynamic Technology Lab Private Ltd Invests $444,000 in The Chemours Company $CC

Dynamic Technology Lab Private Ltd acquired a new stake in shares of The Chemours Company (NYSE:CC) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 28,039 shares of the specialty chemicals company’s stock, valued at approximately $444,000.

Other hedge funds also recently bought and sold shares of the company. Amalgamated Bank boosted its holdings in shares of Chemours by 1.7% during the 3rd quarter. Amalgamated Bank now owns 43,528 shares of the specialty chemicals company’s stock worth $689,000 after purchasing an additional 740 shares during the last quarter. Man Group plc increased its holdings in shares of Chemours by 0.4% in the second quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company’s stock valued at $3,104,000 after purchasing an additional 979 shares during the last quarter. CWM LLC increased its holdings in shares of Chemours by 32.4% in the third quarter. CWM LLC now owns 5,682 shares of the specialty chemicals company’s stock valued at $90,000 after purchasing an additional 1,392 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Chemours by 3.5% during the second quarter. PNC Financial Services Group Inc. now owns 54,452 shares of the specialty chemicals company’s stock worth $623,000 after buying an additional 1,852 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in Chemours by 18.9% during the second quarter. Tower Research Capital LLC TRC now owns 12,123 shares of the specialty chemicals company’s stock worth $139,000 after buying an additional 1,925 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Stock Performance

Shares of Chemours stock opened at $17.89 on Thursday. The firm has a market cap of $2.69 billion, a PE ratio of -7.21 and a beta of 1.60. The company has a quick ratio of 0.85, a current ratio of 1.78 and a debt-to-equity ratio of 16.33. The Chemours Company has a 52 week low of $9.13 and a 52 week high of $21.85. The business’s fifty day simple moving average is $16.73 and its 200-day simple moving average is $14.80.

Chemours (NYSE:CC) last issued its quarterly earnings data on Thursday, February 19th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. Chemours had a positive return on equity of 41.75% and a negative net margin of 6.41%.The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same period last year, the company earned $0.09 EPS. The company’s quarterly revenue was down 2.2% on a year-over-year basis. Equities analysts forecast that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 13th. Stockholders of record on Friday, February 27th will be paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Friday, February 27th. Chemours’s payout ratio is -14.11%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Royal Bank Of Canada reissued an “outperform” rating and set a $18.00 price objective on shares of Chemours in a research note on Friday, January 16th. Jefferies Financial Group reiterated a “hold” rating and set a $17.00 price target on shares of Chemours in a report on Monday, February 23rd. JPMorgan Chase & Co. boosted their price target on shares of Chemours from $13.00 to $17.00 and gave the company a “neutral” rating in a research report on Monday, February 23rd. UBS Group upped their price objective on shares of Chemours from $18.00 to $23.00 and gave the company a “buy” rating in a report on Monday, February 23rd. Finally, BMO Capital Markets cut their price objective on shares of Chemours from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Monday, February 23rd. Five analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.40.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.